These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
351 related articles for article (PubMed ID: 26611604)
1. Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders. Gessler DJ; Gao G Methods Mol Biol; 2016; 1382():429-65. PubMed ID: 26611604 [TBL] [Abstract][Full Text] [Related]
2. Clinical trials in neurological disorders using AAV vectors: promises and challenges. Mandel RJ; Burger C Curr Opin Mol Ther; 2004 Oct; 6(5):482-90. PubMed ID: 15537049 [TBL] [Abstract][Full Text] [Related]
3. Current development of adeno-associated viral vectors. Romano G Drug News Perspect; 2005 Jun; 18(5):311-6. PubMed ID: 16193103 [TBL] [Abstract][Full Text] [Related]
4. [Gene therapy in neurological diseases]. Głabiński AR Neurol Neurochir Pol; 2001; 35(6):1111-9. PubMed ID: 11987706 [TBL] [Abstract][Full Text] [Related]
9. Gene transfer of human acid sphingomyelinase corrects neuropathology and motor deficits in a mouse model of Niemann-Pick type A disease. Dodge JC; Clarke J; Song A; Bu J; Yang W; Taksir TV; Griffiths D; Zhao MA; Schuchman EH; Cheng SH; O'Riordan CR; Shihabuddin LS; Passini MA; Stewart GR Proc Natl Acad Sci U S A; 2005 Dec; 102(49):17822-7. PubMed ID: 16301517 [TBL] [Abstract][Full Text] [Related]
10. Metabolic changes in the knockout mouse for Canavan's disease: implications for patients with Canavan's disease. Surendran S; Matalon KM; Szucs S; Tyring SK; Matalon R J Child Neurol; 2003 Sep; 18(9):611-5. PubMed ID: 14572139 [TBL] [Abstract][Full Text] [Related]
11. Molecular basis of Canavan's disease: from human to mouse. Surendran S; Matalon KM; Tyring SK; Matalon R J Child Neurol; 2003 Sep; 18(9):604-10. PubMed ID: 14572138 [TBL] [Abstract][Full Text] [Related]
12. Canavan disease: a white matter disorder. Kumar S; Mattan NS; de Vellis J Ment Retard Dev Disabil Res Rev; 2006; 12(2):157-65. PubMed ID: 16807907 [TBL] [Abstract][Full Text] [Related]
13. Adeno-associated virus vectors for gene therapy of neurodegenerative disorders. During MJ; Leone P Clin Neurosci; 1995-1996; 3(5):292-300. PubMed ID: 8914796 [TBL] [Abstract][Full Text] [Related]
14. Potential of AAV vectors in the treatment of metabolic disease. Alexander IE; Cunningham SC; Logan GJ; Christodoulou J Gene Ther; 2008 Jun; 15(11):831-9. PubMed ID: 18401432 [TBL] [Abstract][Full Text] [Related]
15. Adeno-associated virus vector-based gene therapy for monogenetic metabolic diseases of the liver. Junge N; Mingozzi F; Ott M; Baumann U J Pediatr Gastroenterol Nutr; 2015 Apr; 60(4):433-40. PubMed ID: 25594875 [TBL] [Abstract][Full Text] [Related]
16. Gene therapy and peripheral nerve repair: a perspective. Hoyng SA; de Winter F; Tannemaat MR; Blits B; Malessy MJ; Verhaagen J Front Mol Neurosci; 2015; 8():32. PubMed ID: 26236188 [TBL] [Abstract][Full Text] [Related]
19. Gene therapy methods in bone and joint disorders. Evaluation of the adeno-associated virus vector in experimental models of articular cartilage disorders, periprosthetic osteolysis and bone healing. Ulrich-Vinther M Acta Orthop Suppl; 2007 Apr; 78(325):1-64. PubMed ID: 17427340 [TBL] [Abstract][Full Text] [Related]
20. Understanding Niemann-Pick type C disease: a fat problem. Vincent I; Bu B; Erickson RP Curr Opin Neurol; 2003 Apr; 16(2):155-61. PubMed ID: 12644742 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]